ACE inhibition and the kidney: species variation in the mechanisms responsible for the renal haemodynamic response
|
|
- Laurel Craig
- 6 years ago
- Views:
Transcription
1 Editorial review Keywords: ACE inhibition, species variation Departments of Radiology and Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA Correspondence to: Professor Norman K Hollenberg Brigham and Women's Hospital, 75 Francis Street, Boston, MA 2115, USA. Tel: Fax: Accepted for publication 31st March 2 JRAAS 2;1: ACE inhibition and the kidney: species variation in the mechanisms responsible for the renal haemodynamic response M Cecilia Lansang, Norman K Hollenberg Introduction During the past two decades, when effective antihypertensive therapy has clearly reduced the incidence of stroke, and possibly coronary artery disease, the incidence of end-stage renal disease in patients who are predisposed because of hypertension and diabetes has continued to increase. 1 Viewed in this context, the remarkable efficacy of angiotensin-converting enzyme (ACE) inhibition in retarding the progression of nephropathy in patients with diabetes mellitus 2,3 and other forms of nephropathy 4,5 has been especially important. Less clear is the mechanism, or mechanisms, by which ACE inhibition reduces the progression of renal injury. This issue has taken on new importance with the development of an alternative approach to blocking the renin-angiotensin-aldosterone system (RAAS) at the AT 1 -receptor level. There are two schools of thought,reflecting the two main actions of ACE inhibitors. One argues that the influence of ACE inhibition on angiotensin II (Ang II) formation plays a minor role in changing natural history and that the important element involves inhibition of kininase II, and thereby activation of a host of vasodilator pathways involving bradykinin (BK), prostaglandin (PG), and nitric oxide (NO). 6 The alternative school of thought argues that the crucial action of the ACE inhibitor involves a reduction in Ang II formation: as there is significant intrarenal non-ace-dependent Ang II generation in humans, the AT 1 -receptor antagonists offer an additional potential as they will block the RAAS more effectively. 7 In a recent review, the possibility was raised that there were important species differences in the pathway by which ACE inhibition influences the kidney. 8 In this essay, we undertake to review the literature systematically, to ascertain whether examination of the evidence in detail will support this contention. Criteria An exhaustive literature search was performed, and from this we gathered the numerous range of measures that the various authors have used to assess the mechanisms by which ACE inhibitors act. These approaches are summarised in Table 1. One can measure the concentration of the relevant hormones in arterial or renal venous plasma. As one example, a range of studies have been made that involve measurement of BK, prostaglandins, and the byproducts of nitric oxide synthesis. As a second approach, one can assess the influence of these hormones through measurement of the biological response following the administration of a range of specific blockers. Thus, if an Ang II antagonist and an ACE inhibitor at the top of their dose-response curves induce an identical renal haemodynamic response, it seems unlikely that an additional action of the ACE inhibitor is involved. In what is probably a more rigorous experiment, one can add one of these agents to the maximum dose of the other to see if an additional response can be recruited. If an ACE inhibitor is given after Ang II antagonist pre-treatment at the top of its dose-response, further response would indicate an action beyond Ang II blockade,whereas a lack of additional vasodilation would suggest that ACE inhibitors act primarily through Ang II. As yet another approach, one can block the alternative vasodilator pathways in ACE inhibitor-treated models with antagonists to BK, prostaglandin synthesis, or nitric oxide synthesis, to ascertain whether a physiological response to one or more of these hormones had been triggered. For example, if the renal blood flow (RBF) induced by an ACE inhibitor is blunted by a kinin receptor antagonist, it is likely that kinins play a role in ACE inhibitor-induced vasodilation. On the other hand, an ACE inhibitor can be given following blockade of prostaglandins and kinins, to see if a further response can be elicited. If a kinin receptor antagonist or kallikrein inhibitor is followed by ACE inhibition and further response is obtained, then some other mechanism, most likely Ang II, is implicated. If no further response is seen, then kinins are solely responsible for the renal vasodilation. By the same reasoning, an ACE inhibitor given after pre-treatment with a non-steroidal anti-inflammatory drug (NSAID) would elicit a further rise in RBF if mechanisms other than prostaglandins are involved, and no further response if prostaglandins alone caused the vasodilation. Since the latter provides more direct evidence of the action of ACE inhibitors than measurement of hormone levels, we have given this approach major emphasis in our analysis. Species As our knowledge of the detailed action of ACE inhibitors derives largely from animal studies, it is important to explore species differences. If no evidence of species variation is found, it is very 119
2 Table 1 Criteria for the mechanism of ACE inhibition. I Measured renal blood flow A. Ang II antagonist compared with ACE inhibitor 1. Same effect B. Ang II antagonist followed by ACE inhibitor 1. No further response C. Kallikrein inhibitor followed by ACE inhibitor 1. No further response D. Kinin antagonist followed by ACE inhibitor 1. No further response E. NSAID followed by ACE inhibitor 1. No further response F. ACE inhibitor followed by kinin antagonist 1. No blunting of response 2 Blunting of response Figure 1 Mean renal blood flow (RBF) in five groups of sodium-restricted dogs pre- and 1-minutes postenalaprilat (.2 mg/kg IV). Group one was given enalaprilat alone and also served as a time control; group two was given saralasin, 1 µg/kg/min IV continuously, and then enalaprilat; group three was given saralasin, 1 µg/kg/min i.a. continuously and then enalaprilat; group four was given B563, 27 µg/min i.a. continuously, and then enalaprilat; group five was given saralasin, 1 µg/kg/min IV, and B563, 27 µg/min i.a. and then enalaprilat. The difference between the control value and value after enalaprilat for each experiment was calculated and subjected to one-way analysis of variance with repeated measures. After analysis of variance, the mean changes were compared between the five groups of experiments by Duncan's new multiple range test. p<.1, group one vs groups two, three, four, and five; p<.5, group five vs groups two and four. II. Measured hormones after ACE inhibition A. Bradykinin/kinin B. PG C. Nitric oxide D. Angiotensin 5 4 Pre-enalaprilat Post-enalaprilat n=6 likely that the mechanisms responsible in animal models also apply to humans. If, on the other hand, evidence of species variation is found, then we must be much more cautious in transferring the studies from animal models to humans. We have thus endeavoured to tease out the various experiments on the three species most commonly used for studying ACE inhibition, the dog, the rat, and the rabbit, and have attempted to compare them with the more limited human studies. As the analysis evolved, it became apparent to us that there were similarities between the first two species, the rat and dog, and thus they will be discussed together. The findings in the rabbit, on the other hand, appear to differ, and they will be reviewed separately. Evidence in dogs and rats In the dog and the rat, there are numerous data to support the contributions of both the RAAS and the kallikrein-kinin system (KKS) to the renal action of ACE inhibition.to illustrate, Zimmerman et al., studied the renal haemodynamic effects of enalaprilat in dogs. 9 When superimposed on administration of the Ang II antagonist, saralasin, enalaprilat still produced an increase in RBF, suggesting that the action of ACE inhibition could not be totally accounted for by Ang II. The BK antagonist B563 likewise partly attenuated the effect of enalaprilat on RBF. When given together, saralasin and B563 produced a much greater response. In this study, the RAAS and BK seemed to contribute equally in the RBF response. 9 (Figure 1). In the split hydronephrotic kidney model in rats, both the BK B2 receptor antagonist, HOE 14, and the Ang II antagonist valsartan blunted the renal vasodilation induced by quinapril, but the effect of HOE 14 was more marked than that of valsartan suggesting a greater influence of the kinins. 1 Numerous additional studies have supported a role for kinins in the renal action of ACE RBF (ml/min) Time contr 1 IV Sar 2 IA Sar 3 Group B563 Sar+B inhibitors. In dogs infused with EXP3174, an active metabolite of losartan, captopril induced an additional increase in RBF, which almost completely disappeared when the BK B2 antagonist HOE 14 was infused together with captopril. 11 Similarly, cilazaprilat increased RBF in dogs infused with the Ang II antagonist E4177; this increase was abolished by the subsequent infusion of the BK B2 receptor antagonist NAAB. 12 Further vasodilator response to ACE inhibition in the presence of Ang II blockade has been shown in dogs elsewhere. 13,14 In volume-expanded dogs treated with deoxycorticosterone acetate (DOCA) and a high-salt (HS) diet, the infusion of the BK B2 receptor antagonist CH 2 -D-Arg-[Hyp 3, Thi 5,8,D-Phe 7 ]BK inhibited the increase in effective renal plasma flow (ERPF) induced by either captopril or imidaprilat. 15 At the other extreme of volume in the acute water deprivation rat model given furosemide, the BK antagonist HOE 14 opposed the decrease in efferent arteriolar resistance caused by enalaprilat. 16 The kallikrein inhibitor aprotinin reduced the renal vasodilator effect of the ACE inhibitor YS-98 in dogs. 17 Taken as a whole, the contribution of kinins to the renal haemodynamic action of ACE inhibition in rats and dogs is unambiguous. A similar logic and results follow treatment with agents that block prostaglandin synthesis. In 12
3 Figure 2 Line graphs showing laser Doppler cortical (left panel) and papillary (right panel) blood flow signals in the control period and after administration of DuP 753 and captopril in rats given vehicle (n=6) or a kinin antagonist (2.5 µg/min, n = 4). Control cortical blood flow signal averaged and V in rats given vehicle or the kinin antagonist, respectively. Control papillary blood flow averaged V in vehicle-treated rats. Baseline papillary blood flow fell from to V after the kinin antagonist. Significant difference from control; significant difference from corresponding value in vehicle-infused group. Kinin antagonist Vehicle Cortical blood flow (% of control) Papillary blood flow (% of control) Control DuP 753 DuP captopril 8 Control DuP 753 DuP captopril dogs pre-treated with indomethacin, the renal vasodilator effect of the ACE inhibitor YS-98 was prevented, implying a possible PG-mediated effect. 17 In agreement, in dogs pre-treated with indomethacin, the increase in RBF caused by the ACE inhibitor SA-446 was suppressed. 18 However, other studies do not support a crucial role of PG. In salt-replete dogs given captopril during saralasin infusion, captopril did not increase RBF, but in those dogs that were treated with the prostaglandin synthesis inhibitor indomethacin, captopril increased RBF by 18%. 19 In a parallel study by the same group, nonhypotensive haemorrhage was utilised in dogs to increase plasma renin activity (PRA). Captopril did not cause a further increase in RBF in those treated with saralasin, but again elicited an increase in RBF in the dogs treated with indomethacin. 2 In dogs on a low-salt (LS) diet pretreated with either of two prostaglandin synthesis inhibitors, indomethacin or meclofenamate, captopril caused a marked increase in RBF, indicating that the acute renal vasodilator effect of captopril does not depend on renal prostaglandins. 21 In the same manner, the RBF response to captopril was not attenuated in dogs on a standard diet pre-treated with indomethacin. 22 The possibility that a different contribution of separate intrarenal vascular pathways contributed to renal responses was suggested by Fenoy et al. 23 In rats pre-treated with the Ang II antagonist DUP 753, papillary blood flow increased by 7% after administration of captopril; this rise was blocked by the kinin receptor antagonist D-Arg, [Hyp 3, Thi 5,8,D-Phe 7 ]-BK. On the other hand,captopril did not produce a further increase in cortical blood flow after pre-treatment with the Ang II antagonist losartan. These observations suggest that kinins mediate the response to ACE inhibition in terms of papillary blood flow and Ang II does so for cortical blood flow (Figure 2). The influence of salt intake on renal responses in the rat and dog One of the possible contributors to variation in the renal response to ACE inhibition is the state of the RAAS at the time of the study. One simple hypothesis would be that the reduction in Ang II formation dominates the renal vascular response to ACE inhibition in settings in which the renin system is activated, as in the case of the LS diet. Conversely, the contribution of the renin system to renal vascular tone, and thus the renal vascular response to ACE inhibition, might be blunted by a HS diet,which would have as its consequence a larger influence of non-renin-dependent mechanisms. In rats on a LS diet pre-treated with saralasin, captopril did not further decrease renal vascular resistance (RVR). In rats on a HS diet first treated with the kallikrein inhibitor aprotinin, captopril likewise did not change RVR. 24 Thus, Ang II was the dominant mechanism in rats on a LS diet whereas kinins exerted their main influence during HS balance. In a study in rats on a LS diet, one group was given saralasin and another group captopril. There was no significant difference in the RBF response between the two groups, suggesting that their mechanism was the same, i.e. blockade of Ang II. 25 The same conclusion was reached when a group of dogs on a LS diet underwent a similar experiment. Those that received the Ang II antagonist saralasin had the same RBF as those that received the ACE inhibitor captopril. 26,27 A number of observations do not conform to this simple model. Prior inhibition of BK B2 receptors with icatibant did not prevent the increase in RBF elicited by enalaprilat in dogs on a HS diet, but this rise was prevented in dogs on a LS diet, indicating that the RAAS was operative in the former and the kinins in the latter. 28 Likewise, in dogs studied either on LS or normal salt (NS) diet, the BK B2 receptor antagonist HOE 14 caused a partial blunting of 121
4 Figure 3 Summary of number of articles supporting either a major angiotensin II (Ang II) dependent pathway or a kinin-prostaglandin(pg)-nitric oxide(no) mechanism. Dominant Ang ll-dependent mechanism Major kinin-pg-no effect Number of articles Dogs Rats Rabbits Humans the increase in RBF induced by ramipril only in the LS group, again suggesting a role for BK in RBF regulation primarily during sodium deprivation. 29 Zimmerman et al. reported that saralasin infusion abolished the renal haemodynamic effect of captopril or enalapril in sodium-replete dogs, but did not completely eliminate this effect in sodiumrestricted dogs. 3 Again, it is possible that kinins are operative in the LS state. Collectively, the evidence in rats and dogs point to a combination of Ang II blockade and kallikrein-kinin system (KKS) activation in the mechanism of ACE inhibition. Under some circumstances, the KKS, like the RAAS, is activated under conditions of LS balance. 31 Evidence in rabbits Unlike the dog and rat, the majority of the available literature in the rabbit points to the RAAS as the dominant system, and fails to support the KKS as a major mediator underlying the renal response to ACE inhibition (Figure 3). In one early study, rabbits on a LS diet were given infusions of either the ACE inhibitor captopril or the Ang II antagonist saralasin. RBF increased to a similar extent in response to each of these two agents, suggesting that they shared the same action, i.e. interruption of the RAAS. 32 In a later study, Hollenberg and Passan studied rabbits given DOCA and HS diet to suppress the renin system, a strategy designed to highlight non-renindependent mechanisms. 33 Saralasin completely prevented the captopril-induced vasodilator response, attributing the ACE inhibitor effect to a decrease in Ang II formation. (Figure 4) Three additional reports mitigate against a role for kinins in this species. The increase in RBF caused by either ramiprilat or captopril in rabbits on a standard diet was not influenced by the presence of the BK antagonist HOE 14. Furthermore, ramiprilat and captopril produced little further increase in RBF in the presence of losartan. 34 HOE 14 likewise did not prevent the renal vasodilation produced by perindoprilat in newborn rabbits. 35 In another study in rabbits, combined inhibition of ACE (using captopril) and the neutral Figure 4 Captopril induced an increase in renal blood flow (RBF) in rabbits despite suppression of the reninangiotensin-aldosterone system (RAAS) by a high-salt diet, supplemented by DOCA treatment. Note that saralasin, the angiotensin antagonist, prevented entirely the renal vascular response, suggesting that the captopril-induced increase in RBF reflected a reduction in angiotensin II (Ang II) formation. RBF (ml/g/min) Superimposed on saralasin Time endopeptidase EP24 11 (using SCH 3937), produced a small increase in RBF compared with vehicle treatment. Pre-treatment with the BK antagonist HOE 14 did not influence the renal effects of captopril and SCH3937,suggesting that their influences are chiefly mediated by pathways not involving BK. 36 There is only one discordant study. In rabbits on normal rabbit chow, captopril caused an increase in RBF in the presence of either the Ang II antagonist losartan or saralasin. During a constant infusion of the BK B2 receptor antagonist BkA, captopril likewise increased RBF. During the combined infusion of losartan and BkA, however, the renal vasodilator effect of captopril was eliminated. 37 Taken as a whole, the data suggest that suppression of Ang II formation plays a larger role than does a reduction in BK degradation in the renal vascular response to ACE inhibition in the rabbit, compared with the rabbit and dog. 122
5 Abbreviations ACE Ang II BK DOCA ERPF HS KKS LS NO NS NSAID PG RAAS RBF RVR PRA angiotensin converting enzyme angiotensin II bradykinin deoxycorticosterone acetate effective renal plasma flow high salt kallikrein-kinin system low salt nitric oxide normal salt non-steroidal inflammatory drug prostaglandin renin-angiotensin-aldosterone system renal blood flow renal vascular remittance plasma renin activity Evidence in humans Despite the fact that the use of ACE inhibitors in treating human disease is widespread, their mode of action is still unclear, as the information available in humans is limited. Since the infusion of blockers into human subjects to study renal haemodynamic effects involves considerable time and expense, the measurement of plasma levels of the appropriate substances has been used by several investigators. A study in normotensive males showed that captopril increased the levels of PGE 2 -M, a potent vasodilator metabolite of prostaglandin E2, either on a LS or HS diet. There was no change in the plasma levels of 6-keto-prostaglandin F 1a (the stable product of prostacyclin), nor of thromboxane B 2 (the stable product of thromboxane A 2 ). 38 The same group evaluated prostaglandin levels in subjects with essential hypertension on a LS diet given captopril. They found a significant increase in prostaglandin E 2 metabolites and F 2a metabolites, with a decrease in levels of 6-keto-F 1a and no change in thromboxane B A few studies have been designed to evaluate the renal haemodynamic mechanisms of ACE inhibition. Hollenberg et al. demonstrated that infusion of either captopril or saralasin increased RBF in healthy individuals on a LS diet. The similar response was ascribed to a shared action, i.e. interference of the RAAS. Moreover, captopril caused a decrease in plasma Ang II concentration without any effect on circulating BK levels. 4 In a comparative analysis of the renal haemodynamic response to pharmacological interruption of the RAAS with ACE inhibitors, Ang II antagonists and renin inhibitors, in a model involving restriction of salt intake to activate the renin system in healthy young volunteers, the renal haemodynamic responses to Ang II antagonists and to renin inhibitors were comparable, and exceeded substantially the response to ACE inhibition, as shown in Figure This pattern of response would suggest that, in this regard, the human resembles the rabbit, with the action of ACE inhibition on the kidney predominantly reflecting a reduction in Ang II formation. This observation found strong support in the recent study on normotensive and hypertensive subjects in LS balance where the administration of captopril alone, captopril plus the BK receptor antagonist icatibant (HOE 14), or losartan alone decreased RVR to a similar extent. Again BK did not seem to contribute significantly to the mechanism of ACE. 42 Overall, available data suggest that there are important species differences in the mechanism(s) responsible for the renal haemodynamic response to ACE inhibition. In the rat and dog, there appears to be a substantial contribution from BK-dependent mechanisms. In the rabbit and humans, on the other hand, any contribution from this pathway appears to be minor, and the dominant mechanism involves a reduction in Ang II formation (Figure 3). Chi square analysis of the number of articles favouring either a dominant Ang II-dependent mechanism or a major kinin-pg- NO effect supports the latter for the first group (dogs and rats combined) and the former for the second group (rabbits and humans combined) (X 2 = 7.38, p<.1). Given growing evidence that chymase contributes to intrarenal Ang II formation via pathways that are not sensitive to ACE inhibition, the therapeutic implications of the Ang II antagonist class in humans are obvious. Acknowledgments This work was supported in part by National Institutes of Health (grants T32 HL-769, NCRR GCRC M1RR26376, P1AC59916, 1P5ML 53-1, and 1 R1 DK ) and Astra Pharmaceuticals. We are grateful for the assistance of Ms Diana Capone in the preparation and submission of this manuscript. References 1 Porush JG. Hypertension and chronic renal failure: the use of ACE inhibitors. Am J Kidney Dis 1998;31: Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995;99: Parving HH, Rossing P, Hommel E et al. converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kidney Dis 1995;26: The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349: Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354: Mori M, Akatsuka N, Fukazawa M et al. Endotheliumdependent relaxation by angiotensin converting enzyme inhibitors in canine femoral arteries. Am J Physiol 1994;266:H583-H Hollenberg NK. ACE inhibitors, AT1 receptor blockers, and the kidney. Nephrol Dial Transplant 1997;12: Hollenberg NK. Corcoran Lecture: Implications of species difference for clinical investigation: studies on the reninangiotensin system. Hypertension 2;35:
6 9. Zimmerman BG, Raich PC,Vavrek RJ et al. Bradykinin contribution to renal blood flow effect of angiotensin converting enzyme inhibitor in the conscious sodium-restricted dog. Circ Res 199;66:234(c) Endlich K, Steinhausen M. Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels. J Hypertension 1997;15: Heller J, Kramer HJ, Horacek V. Comparative effects of the angiotensin II receptor blocker EXP 3174 and of the angiotensin converting enzyme inhibitor captopril on renal glomerular hemodynamics in the dog. Kidney Blood Press Res 1997;2: Matsuda H, Hayashi K, Arakawa K et al. Zonalheterogeneity in action of angiotensin converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol 1999;1: Clappison BH,Anderson WP, Johnston CI. Renal hemodynamics and renal kinins after angiotensin converting enzyme inhibition. Kidney International 1981;2: Clappison BH, Anderson WP, Johnston CI. Role of the kallikrein-kinin system in the renal effects of angiotensin converting enzyme inhibition in anesthetized dogs. Clin Exp Pharmacol Physiol 1981;8: Naitoh M, Suzuki H, Arakawa K et al. Role of kinin and renal AngII blockade in acute effects of ACE inhibitors in lowrenin hypertension. Am J Physiol 1997;272:H679-H Kon V, Fogo A, Ichikawa I, Hellings SE et al. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44: Abe Y, Miura K, Imanishi M et al. Effects of an orally active converting enzyme inhibitor (YS-98) on renal function in dogs. J Pharmacol Exp Ther 198;214: Miura K,Yukimura T, Imanishi M et al. Effect of SA-446, an angiotensin-converting enzyme inhibitor, on renal function in anesthetized dogs; special reference to arachidonic acid metabolites. J Cardiovasc Pharmacol 1985;7: Wong PC, Zimmerman BG, Kraft E et al. Pharmacological evaluation in conscious dogs of factors involved in the renal vasodilator effect of captopril. J Pharmacol Exp Ther 1981; 219: Wong PC, Zimmerman BG. Mechanism of captopril(c)induced renal vasodilation in anesthetized dogs after nonhypotensive hemorrhage. N Pharmacol Exp Ther 198;215: Oliver JA, Sciacca RR, Cannon PJ. Renal vasodilation by converting enzyme inhibition: role of renal prostaglandins. Hypertension 1983;5: Tobia AJ, Giardino EC. Renal vasodilator responses to captopril in dogs pre-treated with indomethacin (41157). Proc Soc Exp Biol Med 1981;167: Fenoy FJ, Scicli G, Carretero O, Roman RJ. Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 1991;17: Johnston PA, Bernard DB, Perrin NS et al. Control of rat renal vascular resistance during alterations in sodium balance. Circ Res 1981;48: Mimran A, Casellas D, Dupont M. Indirect evidence against a role of the kinin system in the renal hemodynamic effect of captopril in the rat. Kidney Int 198;18: Kimbrough HM, Vaughan ED, Carey RM et al. Effect of intrarenal angiotensin II blockade on renal function in conscious dogs. Circ Res 1977;4: Burger BM, Hopkins T, Tulloch A et al. The role of angiotensin in the canine and vascular response to barbiturate anesthesia. Circ Res 1976;38: Omoro SA, Majid DSA, Ed(c)Dahr SS et al. Kinin influences on renal regional blood flow responses to angiotensinconverting enzyme inhibition in dogs. Am J Physiol 1999;276:F271-F Heller J, Kramer HJ, Horacek V. The effect of kinin and prostaglandin inhibitors on the renal response to angiotensinconverting enzyme inhibition: a micropuncture study in the dog. Pfugers Arch 1994;427: Zimmerman BG, Goering JL, Raich PC. Resistance to blockade by saralasin of effect of ACE inhibitors in conscious sodium(c)restricted dog. Am J Physiol1988;255:F944-F Wong PY,Talamo RC, Williams GH et al. Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture. J Clin Invest 1975;55: Mimran A, Guiod L, Hollenberg NK. The role of angiotensin in the cardiovascular and renal response to salt restriction. Kidney Int 1974;5: Hollenberg NK, Passan DR. Specificity of renal vasodilation with captopril: saralasin prevents the response in the DOCA-treated, salt loaded rabbit. Life Sci 1982;31: Chen K, Zimmerman BG. Comparison of renal hemodynamic effect of ramiprilat to captopril; possible role of kinins. J Pharmacol Exp Ther 1994;27: Toth-Heyn P, Mosig D, Guignard JP. Role of bradykinin in the neonatal renal effects of angiotensin converting enzyme inhibition. Life Sci 1998;64: Tomoda F, Lew RA, Smith Al et al. Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases and in conscious rabbits. Br J Pharmacol 1996;119: Haij-Ali AF, Zimmerman BG. Kinin contribution to renal vasodilator effect of captopril in rabbit. Hypertension 1991;17: Swartz SL, Williams GH, Hollenberg NK et al. Captoprilinduced changes in prostaglandin production: relationship tovascular responses in normal man. J Clin Invest 198;65: Crantz FR, Swartz SL, Hollenberg NK et al. Role of prostaglandins in the hypotensive response to captopril in essential hypertension. Clin Res 1979;27: Hollenberg NK,Williams GH,Taub KJ et al. Renal vascular response to interruption of the renin-angiotensin system in normal man. Kidney Int 1977;12: Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue:evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32: Gainer JV, Morrow JD, Loveland A et al. Effect of bradykinin-receptor blockade on the response to angiotensinconverting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med1998;339: Erratum The following error appeared in the March 2 issue of the JRAAS, reference: Park JB, Intengan HD, Schiffrin EL. Reduction of resistance artery stiffness by treatment with the AT 1 -receptor antagonist losartan in essential hypertension. JRAAS 2; 1: The date of acceptance of the final manuscript for publication should have been 8th February 2 and not 6th December
Plasma aldosterone concentration in the patient with diabetes mellitus Rapid Communication
Kidney International, Vol. 65 (2004), pp. 1435 1439 Plasma aldosterone concentration in the patient with diabetes mellitus Rapid Communication NORMAN K. HOLLENBERG, RADOMIR STEVANOVIC, ANUPAM AGARWAL,
More informationmodulating the tubuloglomerular feed-back mechanism in the canine kidney; Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, U.S.A.
J. Physiol. (1986), 380, pp. 35-43 35 With 3 text-figures Printed in Great Britain RENAL VASOCONSTRICTOR RESPONSE TO HYPERTONIC SALINE IN THE DOG: EFFECTS OF PROSTAGLANDINS, INDOMETHACIN AND THEOPHYLLINE
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence?
Reviews ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence? George L. Bakris, MD; 1 and Matthew Weir, MD 2 Although angiotensin-converting
More informationBRADYKININ-RECEPTOR BLOCKADE AND RESPONSE TO ACE INHIBITOR IN NORMOTENSIVE AND HYPERTENSIVE SUBJECTS
BRADYKININ-RECEPTOR BLOCKADE AND RESPONSE TO ACE INHIBITOR IN NORMOTENSIVE AND HYPERTENSIVE SUBJECTS EFFECT OF BRADYKININ-RECEPTOR BLOCKADE ON THE RESPONSE TO ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN
More informationROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN TYPE I DIABETIC NEPHROPATHY DR.NASIM MUSA
ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN TYPE I DIABETIC NEPHROPATHY DR.NASIM MUSA Type I IDDM is characterized by The abrupt onset of symptoms Insulinopenia
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers PROTEINURIA
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationIn general, angiotensin-converting enzyme (ACE)
AJH 1999;12:195S 203S Are Drugs That Block the Renin-Angiotensin System Effective and Safe in Patients With Renal Insufficiency? Matthew R. Weir Extensive clinical experience with angiotensinconverting
More informationData Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition
Vascular Bi o l o g y Work i n g Gro u p c/o Medical Education Consultants, In c. 25 Sy l van Road South, We s t p o rt, CT 06880 Chairman: Carl J. Pepine, MD Professor and Chief Division of Cardiovascular
More informationThe role of angiotensin II (AngII) in maintaining
AJH 1999;12:705 715 Chronic Captopril Administration Decreases Vasodilator Responses in Skeletal Muscle Arterioles Jefferson C. Frisbee, David S. Weber, and Julian H. Lombard Changes in arteriolar reactivity
More informationRenal Damage. Captopri 1 Ena 1 apr i 1 Kinins
CLIN. AND EXPER.THEORY AND PRACTICE, A9(2&3), 409413 (1987) PREVENTION OF RENAL DAMAGE AND DECREASE OF URINARY KININS EXCRETION BY CHRONIC TREA"TS WITH ENALAPRIL AND CAPTOPRIL IN STROKEPRONE SPONTANEOUSLY
More informationThe retinal renin-angiotensin system: implications for therapy in diabetic retinopathy
(2002) 16, S42 S46 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh : implications for therapy in diabetic retinopathy AK Sjølie 1 and N Chaturvedi 2 1 Department
More informationPerioperative use of angiotensin blockade
Perioperative use of angiotensin blockade Dr Fiona Chow on behalf of A/Prof Ian Fraser Epworth HealthCare 1 surgical_operation_with_surgeons_and_nurses_royalty_free_clipart_picture_100616-172691-620048.jpg
More informationTHE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM The renin angiotensin system (RAS) or the renin angiotensin aldosterone system (RAAS) is a hormone system that is involved in the regulation of the plasma sodium
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationPharmacology - Problem Drill 11: Vasoactive Agents
Pharmacology - Problem Drill 11: Vasoactive Agents Question No. 1 of 10 1. Vascular smooth muscle contraction is triggered by a rise in. Question #01 (A) Luminal calcium (B) Extracellular calcium (C) Intracellular
More informationGlomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus
Kidney International, Vol. 63 (2003), pp. 172 178 VASCULAR BIOLOGY HEMODYNAMICS HYPERTENSION Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus NORMAN K.
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationThe effects of angiotensin II on blood perfusion in the rat renal papilla
9325 Journal of Physiology (1999), 519.1, pp. 273 278 273 The effects of angiotensin II on blood perfusion in the rat renal papilla L. L. Walker, A. A. J. Rajaratne, J. R. Blair-West and P. J. Harris Department
More informationMetabolic Consequences of Anti Hypertensives: Is It Clinically Important?
Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?,FACA,FICA,MASH,FVBWG,MISCP CONSULTANT OF CARDIOLOGY DIRECTOR OF PORT-FOUAD HOSPITAL CCU Consideration of antihypertensive agents
More informationAntihypertensive drugs: I. Thiazide and other diuretics:
Clinical assessment of hypertensive patient: You have to take history regarding the presence of other risk factors for CAb like diabetes mellitus, smoking, etc. Take history whether the patient takes medications
More informationAmlodipine plus Lisinopril Tablets AMLOPRES-L
Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)
More information1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias
1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias Only need to know drugs discussed in class At the end of this section you should
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationheart failure John McMurray University of Glasgow.
A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril
More informationby Converting Enzyme Inhibition in Essential Hypertensives
Correction of Abnormal Renal Blood Flow Response to Angiotensin 11 by Converting Enzyme Inhibition in Essential Hypertensives Jamie Redgrave, Steven Rabinowe, Norman K. Hollenberg, and Gordon H. Williams
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationSince the initial description of angiotensin II mediated
CLINICAL CARDIOLOGY: PHYSICIAN UPDATE Manipulation of the Renin-Angiotensin System Michael M. Givertz, MD Since the initial description of angiotensin II mediated hypertension 40 years ago, basic and clinical
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationDRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI
DRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI 3. Vasodilators Drugs which dilate blood vessels ( decrease peripheral vascular resistance) by acting on smooth muscle cells through non-autonomic mechanisms:
More informationEffect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial
Int Urol Nephrol (2012) 44:1763 1770 DOI 10.1007/s11255-011-0110-z NEPHROLOGY ORIGINAL PAPER Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised,
More informationThe therapeutic potential of adenoviral gene therapy and angiotensine-(1-7) in proteinuric kidney disease Wouden, Esther Anita van der
University of Groningen The therapeutic potential of adenoviral gene therapy and angiotensine-(1-7) in proteinuric kidney disease Wouden, Esther Anita van der IMPORTANT NOTE: You are advised to consult
More informationPaul M McKie, Alessandro Cataliotti, Guido Boerrigter, Horng C Chen, Fernando L Martin, and John C Burnett Jr
Cardiorenal Enhancing and Aldosterone Suppressing Actions of a Novel Designer Natriuretic Peptide in Experimental Hypertension with Ventricular Pressure Overload Paul M McKie, Alessandro Cataliotti, Guido
More informationRenal Blood flow; Renal Clearance. Dr Sitelbanat
Renal Blood flow; Renal Clearance Dr Sitelbanat Objectives At the end of this lecture student should be able to describe: Renal blood flow Autoregulation of GFR and RBF Regulation of GFR The Calcuation
More informationKerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009
Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 DR. KERRY COOPER IS ON THE SPEAKER BUREAU OF AMGEN, ABBOTT, GENZYME, SHIRE, AND BMS DR. COOPER IS ALSO INVOLVED IN CLINICAL
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More information9/17/2015. Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14.
0 1 2 Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14. 3 Slide notes: Large trials such as ALLHAT, LIFE and ASCOT show that the majority of patients with hypertension will require multiple
More informationTreatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor
CLINICAL RESEARCH STUDY Treatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor Philip Kam-Tao Li, MD, Bonnie Ching-Ha Kwan, MBBS, Kai-Ming Chow, MBChB, Chi-Bon Leung,
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationSalt Sensitivity: Mechanisms, Diagnosis, and Clinical Relevance
Salt Sensitivity: Mechanisms, Diagnosis, and Clinical Relevance Matthew R. Weir, MD Professor and Director Division of Nephrology University of Maryland School of Medicine Overview Introduction Mechanisms
More informationACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD )
005 16 175-180 1 1 ( chronic kidney disease, CKD ) 003 ( end-stage renal disease, ESRD ) Angiotensin-converting enzyme inhibitors ( ) angiotensin receptor blockers ( ) nondihydropyridine ( NDHP ) / NDHP
More informationProceeding of the LAVC Latin American Veterinary Conference Oct , 2009 Lima, Peru
Close this window to return to IVIS www.ivis.org Proceeding of the LAVC Latin American Veterinary Conference Oct. 16-19, 2009 Lima, Peru Reprinted in the IVIS website with the permission of the LAVC http://www.ivis.org/
More informationVALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
More informationRemission and Regression of Diabetic Nephropathy
515 Review Remission and Regression of Diabetic Nephropathy Hirofumi MAKINO, Yoshio NAKAMURA, and Jun WADA Diabetic nephropathy has become the single largest cause of end-stage renal disease (ESRD) worldwide.
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationBradykinin B 2 Receptor Modulates Renal Prostaglandin E 2 and Nitric Oxide
(Hypertension. 1997;29:757-762.) 1997 American Heart Association, Inc. Bradykinin B 2 Receptor Modulates Renal Prostaglandin E 2 and Nitric Oxide Helmy M. Siragy; Ayad A. Jaffa; Harry S. Margolius the
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationDifferential effect of angiotensin II on blood circulation in the renal medulla and cortex of anaesthetised rats
Journal of Physiology (2002), 538.1, pp. 159 166 DOI: 10.1013/jphysiol.2001.012921 The Physiological Society 2002 www.jphysiol.org Differential effect of angiotensin II on blood circulation in the renal
More informationSection 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
More informationTread Carefully Because you Tread on my Nephrons. Prescribing Hints in Renal Disease
Tread Carefully Because you Tread on my Nephrons Prescribing Hints in Renal Disease David WP Lappin,, MB PhD FRCPI Clinical Lecturer in Medicine and Consultant Nephrologist and General Physician, Merlin
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationAnalysis of Factors Causing Hyperkalemia
ORIGINAL ARTICLE Analysis of Factors Causing Hyperkalemia Kenmei Takaichi 1, Fumi Takemoto 1, Yoshifumi Ubara 1 and Yasumichi Mori 2 Abstract Objective Patients with impaired renal function or diabetes
More informationACE inhibitors in mild heart failure: first-line or second-line therapy?
European Heart Journal (1990) 11 (Supplement D), 53-57 ACE inhibitors in mild heart failure: first-line or second-line therapy? J. G. F. CLELAND Department of Medicine (Cardiology Section), Hammersmith
More informationIn the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension
In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial
More informationAnalgesic and NSAID-induced Kidney Disease
Analgesic and NSAID-induced Kidney Disease Edited by J.H.STEWART Associate Dean, Western Clinical School University of Sydney, Australia Oxford New York Tokyo Melbourne OXFORD UNIVERSITY PRESS 1993 CONTENTS
More informationHypertension in Systemic Diseases
Hypertension in Systemic Diseases Prof. Andrzej Więcek FRCP (Edin.), FERA Department of Nephrology, Transplantation and Internal Medicine Medical University of Silesia, Katowice, Poland Hypertension in
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More informationConclusion: Dual blockade of the RAAS is safe. and effective in reducing albuminuria in Asian. type 2 diabetic patients with nephropathy.
Original Article Singapore Med J 201 0; 51(2) : 1 51 Dual blockade of the renin-angiotensinaldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy
More informationJun Cheng, MD; Wen Zhang, MMed; Xiaohui Zhang, MMed; Fei Han, MD; Xiayu Li, MD; Xuelin He, MD; Qun Li, MMed; Jianghua Chen, MMed
Research Original Investigation Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients
More informationComparison between the efficacy of double blockade and single blockade of RAAS in diabetic kidney disease
International Journal of Advances in Medicine Gupta A et al. Int J Adv Med. 2018 Aug;5(4):931-935 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20183122
More informationRenal protection by inhibition of the renin-angiotensinaldosterone
Renal protection by inhibition of the renin-angiotensinaldosterone system Tomas Berl Key words: angiotensinconverting enzyme inhibitor, angiotensin receptor blocker, combination therapy, direct renin inhibitor,
More informationCase Study in Chronic Renal Failure
Case Study in Chronic Renal Failure Development of Knowledge Base: There were over 14,500 articles dealing with chronic renal failure entered into PubMed during 2000 2004. A current concept in this array
More informationAn acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
original article http://www.kidney-international.org & 2011 International Society of Nephrology see commentary on page 235 An acute fall in estimated glomerular filtration rate during treatment with losartan
More informationDr. Mehmet Kanbay Department of Medicine Division of Nephrology Istanbul Medeniyet University School of Medicine Istanbul, Turkey.
The uric acid dilemma: causal risk factor for hypertension and CKD or mere bystander? Mehmet Kanbay, Istanbul, Turkey Chairs: Anton H. van den Meiracker, Rotterdam, The Netherlands Claudia R.C. Van Roeyen,
More informationPatterns of Sodium Excretion During Sympathetic Nervous System Arousal. Gregory A. Harshfield, Derrick A. Pulliam, and Bruce S.
1156 Patterns of Sodium Excretion During Sympathetic Nervous System Arousal Gregory A. Harshfield, Derrick A. Pulliam, and Bruce S. Alpert The purpose of this study was to examine Na + handling and regulation
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationThe ability of the kidneys to regulate extracellular fluid volume by altering sodium
REGULATION OF EXTRACELLULAR FLUID VOLUME BY INTEGRATED CONTROL OF SODIUM EXCRETION Joey P. Granger Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi
More informationCLINICIAN INTERVIEW A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY. Interview with Ralph Rabkin, MD
A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY Interview with Ralph Rabkin, MD Dr Rabkin is Professor of Medicine, Emeritus, Active, at Stanford University School of Medicine, Stanford,
More informationChanges in Rats by Captopril
Inhibition of Vascular Permeability Changes in Rats by Captopril J. C. FANTONE, D. SCHRIER, and B. WEINGARTEN, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109
More informationCardiovascular Protection and the RAS
Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular
More informationFAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments
More informationContribution of Thromboxane to Renal Resistance Changes in the Isolated Perfused Hydronephrotic Rabbit Kidney
486 Contribution of Thromboxane to Renal Resistance Changes in the Isolated Perfused Hydronephrotic Rabbit Kidney Akiyoshi Kawasaki and Philip Needleman From the Department of Pharmacology, Washington
More informationRole of Angiotensin II in the Renal Effects Induced by Nitric Oxide and Prostaglandin Synthesis Inhibition
Role of Angiotensin II in the Renal Effects Induced by Nitric Oxide and Prostaglandin Synthesis Inhibition MARIA T. LLINAS, JUAN D. GONZALEZ, EDUARDO NAVA, and F. JAVIER SALAZAR Departamento de Fisiologla,
More informationIn unilateral renovascular hypertension (RVH), prostaglandin
Scientific Contributions Prostaglandin I 2 /E 2 Ratios in Unilateral Renovascular Hypertension of Different Severities Masahito Imanishi, Tetsu Tsuji, Satoko Nakamura, Makoto Takamiya Abstract Differences
More informationStrategies in Cardiovascular Disease and Respiratory Disease
Strategies in Cardiovascular Disease and Respiratory Disease Drug Discovery and Medicinal Chemistry The Renin-Angiotensin Pathway Dr Anna Barnard - Spring 2017 Course Overview Lecture 1: Overview of the
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1Overview of disease epidemiology 1 Losartan is indicated for: Treatment of essential hypertension in adults and in children and adolescent 6 18 years of age. Treatment
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Antihypertensive therapy in diabetic nephropathy GUIDELINES
Antihypertensive therapy in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Adequate control of blood pressure (BP) slows progression
More informationSAFETY IN THE CATH LAB How to Minimise Contrast Toxicity
SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity Dr. Vijay Kunadian MBBS, MD, MRCP Senior Lecturer and Consultant Interventional Cardiologist Institute of Cellular Medicine, Faculty of Medical
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of fish oil
Specific management of IgA nephropathy: role of fish oil Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Early and prolonged treatment with fish oil may retard
More informationACE. Inhibitors. Quiz feedback
ACE Inhibitors Quiz feedback bpac nz better medicin e bpac nz Quiz feedback, ACE inhibitors, 2006 Best Practice Advocacy Centre ACE inhibitors quiz feedback bpac nz Development Team: Rachael Clarke Sonia
More informationResponsiveness vs. basal activity of plasma ANG II as a determinant of arterial pressure salt sensitivity
Am J Physiol Heart Circ Physiol 285: H2142 H2149, 2003. First published July 24, 2003; 10.1152/ajpheart.00200.2003. Responsiveness vs. basal activity of plasma ANG II as a determinant of arterial pressure
More informationNew Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationSeptic Acute Kidney Injury (AKI) Rinaldo Bellomo Australian and New Zealand Intensive Care Research Centre (ANZIC-RC) Melbourne Australia
Septic Acute Kidney Injury (AKI) Rinaldo Bellomo Australian and New Zealand Intensive Care Research Centre (ANZIC-RC) Melbourne Australia Things we really, honestly know about septic AKI AKI is common
More informationAspirin has perhaps the broadest spectrum
AJH 1999;12:784 789 Effect of Aspirin on Blood Pressure in Hypertensive Patients Taking Enalapril or Losartan James J. Nawarskas, Raymond R. Townsend, Michael D. Cirigliano, and Sarah A. Spinler The ability
More informationRenal perfusion and function in healthy African Americans
Kidney International, Vol. 59 (2001), pp. 1037 1043 VASCULAR BIOLOGY HEMODYNAMICS HYPERTENSION Renal perfusion and function in healthy African Americans DEBORAH A. PRICE, NAOMI D.L. FISHER, SUZETTE Y.
More information